Jean-Paul Clozel
Chief Executive Officer (since 2017)
Date of birth: April 3, 1955
Nationality: Swiss and French
Education: Medical degree in France; further training in pharmacology and physiology at the University of Montreal, Canada, and the University of California, San Francisco, US.
Professional background: Practicing cardiologist, 1980–1985; Head of Drug Discovery Group in the Cardiovascular Department of F. Hoffmann-La Roche, 1985–1997; Founder of Actelion in 1997 and CEO 2000–2017.
Other Group functions: Member of the Board of Idorsia Ltd, Chairman of the Board of Idorsia Pharmaceuticals Ltd, member of the Board of Idorsia (Shanghai) Pharmaceuticals Co. Ltd.
Martine Clozel
Executive Vice President, Chief Scientific Officer (since 2017)
Date of birth: December 27, 1955
Nationality: Swiss and French
Education: MD, specialization in pediatrics and in neonatal intensive care, educated at the University of Nancy, France; further training in physiology and pharmacology at McGill University, Montreal, Canada, and at the University of California, San Francisco, US.
Professional background: Assistant professor, Neonatology; Scientific expert, leader of drug discovery projects, F. Hoffmann-La Roche Ltd; Head of Drug Discovery, Pharmacology & Preclinical Development, Actelion (1997–2009); Chief Scientific Officer, Actelion (2009–2017).
Officer of the Legion of Honour in France.
Other functions: Vice Chair of Board of Trustees, Marcel Benoist Foundation.
Guy Braunstein
Executive Vice President, Chief Medical Officer (since 2022)
Date of birth: November 19, 1956
Nationality: French
Education: MD, pulmonologist and PhD in life science, Paris University, France.
Professional background: Merck Serono, Chief Medical Officer; Serono, Chief Medical Officer International; various executive positions at Astra, Fisons, Rhône-Poulenc Rorer, Glaxo Wellcome, GSK and Chiron; Head of Clinical Development, Actelion (2009–2017), Head of Global Clinical Development, Idorsia (2017–2022).
Other functions: Member of the Board of Directors of the non-listed company 35Pharma
Alberto Gimona
Executive Vice President, Head of Global Clinical Development (since 2022)
Date of birth: March 28, 1960
Nationality: Italian
Education: MD, Pisa University, Italy; Post graduate course in Clinical Pharmacology, Milano University, Italy
Professional background: Various Clinical and Therapeutic Areas leadership positions In Rhone Poulenc Rorer, Novartis, Serono, Merck Serono. Clinical Science Head Actelion (2011-2017), Head of Clinical Development, Actelion /Janssen (2017 -2019), Head of Therapeutic Areas Unit Idorsia (2019 -2022).
Other functions: None
André C. Muller
Executive Vice President, Chief Financial Officer (since 2017)
Date of birth: October 30, 1963
Nationality: French
Education: Master’s degree in Business Administration from EMLYON Business School, Lyon, France.
Professional background: Held various financial positions at Pierre Fabre SA, an international pharmaceutical and dermo-cosmetic company, serving as Chief Financial Officer from 2002 (1994–2011); Chief Financial Officer, Actelion (2013–2017).
Other Group functions: Member of the Board of Idorsia Pharmaceuticals Ltd and Idorsia (Shanghai) Pharmaceuticals Co. Ltd.
Other functions: Member of the Board of Directors of the listed company Carmat SA and the unlisted company Chiron Investments AG.
Chief Science Officer
Martine Clozel
Chief Executive Officer
Jean-Paul Clozel
Chief Financial Officer
André C. Muller
Chief Medical Officer
Guy Braunstein
Head of Global Clinical Development
Alberto Gimona